Trials that use: Odds ratio
New to this method? Read the tutorial →
82 results
- ABCSG-18Independent statistical analysis of ABCSG-18, a randomized phase 3 trial of denosumab in patients with breast cancer receiving aromatase inhibitor therapy, including trial design, fracture, bone mineral density, disease-free survival, bone metastases-free…
- ACTG A5279Independent statistical analysis of ACTG A5279 (NCT01404312), a randomized phase 3 trial comparing a rifapentine-plus-isoniazid regimen with an isoniazid regimen for tuberculosis prevention in people with HIV.
- ACTT-2Independent statistical analysis of ACTT-2, the randomized phase 3 trial of remdesivir plus baricitinib versus remdesivir plus placebo in COVID-19, including time-to-recovery, ordinal-scale, and safety analyses.
- AGO-OVAR 12Independent statistical analysis of AGO-OVAR 12 (NCT01015118), a randomized phase 3 trial of nintedanib or placebo with paclitaxel and carboplatin in first-line ovarian cancer, including progression-free survival, overall survival, response, quality of…
- AMBITIONIndependent statistical analysis of the AMBITION phase 3 trial of first-line ambrisentan and tadalafil combination therapy in pulmonary arterial hypertension, including time-to-event analysis, secondary endpoints, statistical methodology, safety, and interpretation.
- ASCENTIndependent statistical analysis of ASCENT, a randomized phase 3 trial of sacituzumab govitecan versus Treatment of Physician's Choice in participants with refractory or relapsed metastatic triple-negative breast cancer.
- ASPECCTIndependent statistical analysis of ASPECCT, the randomized phase 3 comparison of panitumumab and cetuximab in patients with KRAS wild-type metastatic colorectal cancer, including non-inferiority analysis, hazard ratios, response, patient-reported outcomes, and safety.
- ATLANTICIndependent statistical analysis of ATLANTIC (NCT01347580), a randomized phase 4 trial comparing pre-hospital versus in-hospital initiation of ticagrelor in STEMI patients planned for PCI.
- AURA3Complete statistical analysis of AURA3, the randomized phase 3 trial of osimertinib versus platinum-based doublet chemotherapy in locally advanced or metastatic non-small cell lung cancer, including endpoints, statistical methods, efficacy results, safety,…
- AWARD-6Independent statistical analysis of the randomized phase 3 AWARD-6 trial comparing dulaglutide with liraglutide in type 2 diabetes, including the HbA1c non-inferiority analysis, secondary endpoints, statistical methods, safety, and interpretation.
- BOSTONIndependent statistical analysis of the phase 3 BOSTON trial of selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in multiple myeloma, including PFS, response, overall survival, safety, and statistical methodology.
- BREAKWATERIndependent statistical analysis of the BREAKWATER phase 3 trial of encorafenib plus cetuximab with or without chemotherapy in previously untreated metastatic colorectal cancer, including trial design, primary endpoints, hazard ratios, odds ratios,…
- CALLAIndependent statistical analysis of the CALLA phase 3 trial of durvalumab with chemoradiotherapy in women with locally advanced cervical cancer, including trial design, progression-free survival, overall survival, response endpoints, safety, and statistical…
- CAN-COVIDIndependent statistical analysis of CAN-COVID, a randomized phase 3 study of canakinumab versus placebo for cytokine release syndrome in participants with COVID-19-induced pneumonia, including its primary binary endpoint, logistic regression, odds ratio,…
- CANTATAComplete statistical analysis of the phase 3 CANTATA trial, including trial design, HbA1c efficacy, secondary metabolic endpoints, ANCOVA, logistic regression, confidence intervals, and statistical interpretation.
- CAROLINAIndependent statistical analysis of the CAROLINA phase 3 trial comparing linagliptin with glimepiride in patients with type 2 diabetes, including non-inferiority testing, cardiovascular outcomes, glycaemic control, ANCOVA, Cox regression, and logistic regression.
- CASPIANIndependent statistical analysis of CASPIAN, the randomized phase 3 trial of durvalumab with platinum-based chemotherapy in untreated extensive-stage small cell lung cancer, including overall survival, progression-free survival, response, statistical methodology, and interpretation.
- CASSIOPEIAA complete statistical analysis of the phase 3 CASSIOPEIA trial evaluating daratumumab in transplant-eligible participants with previously untreated multiple myeloma, including trial design, primary endpoints, reported statistical analyses, safety, and interpretation.
- CheckMate-026Independent statistical analysis of CheckMate-026, a randomized phase 3 trial of nivolumab versus investigator's choice chemotherapy as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer.
- CheckMate-037Independent statistical analysis of CheckMate-037, a randomized phase 3 trial of BMS-936558 (nivolumab) versus Investigator's Choice in unresectable or metastatic melanoma.
- CheckMate-141Independent statistical analysis of CheckMate-141, the randomized phase 3 trial of nivolumab versus investigator's choice therapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
- CheckMate-459Independent statistical analysis of CheckMate-459, a randomized phase 3 trial comparing nivolumab with sorafenib as first treatment in advanced hepatocellular carcinoma, including overall survival, response, progression-free survival, statistical methods, and interpretation.
- CheckMate-816Independent statistical analysis of CheckMate-816, a randomized phase 3 trial of nivolumab plus platinum-doublet chemotherapy versus chemotherapy alone in early-stage non-small cell lung cancer.
- CheckMate-9ERIndependent statistical analysis of CheckMate-9ER, the phase 3 randomized trial of nivolumab combined with cabozantinib versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma.
- CLEOPATRAIndependent statistical analysis of CLEOPATRA, the randomized phase 3 trial of pertuzumab plus trastuzumab and docetaxel versus placebo plus trastuzumab and docetaxel in previously untreated HER2-positive metastatic breast cancer.
- CONTACT-01Independent statistical analysis of CONTACT-01, a randomized phase 3 trial of atezolizumab plus cabozantinib versus docetaxel in metastatic non-small cell lung cancer previously treated with an anti-PD-L1/PD-1 antibody and platinum-containing chemotherapy.
- CONTACT-03Independent statistical analysis of CONTACT-03, a randomized phase 3 trial of atezolizumab plus cabozantinib versus cabozantinib alone in participants with advanced renal cell carcinoma after immune checkpoint inhibitor treatment.
- CRYSTALIndependent statistical analysis of the CRYSTAL phase 3 trial of cetuximab plus FOLFIRI versus FOLFIRI alone in EGFR-expressing metastatic colorectal cancer, including progression-free survival, overall survival, response, statistical methods, and interpretation.
- DUO-EIndependent statistical analysis of the phase 3 DUO-E trial evaluating durvalumab with or without olaparib as maintenance therapy after first-line treatment of advanced and recurrent endometrial cancer.
- EMBRACAIndependent statistical analysis of the EMBRACA phase 3 trial of talazoparib versus physician's choice treatment in advanced and/or metastatic breast cancer patients with BRCA mutation, including progression-free survival, response, overall survival, quality…
- EMPULSEIndependent statistical analysis of the EMPULSE phase 3 trial of empagliflozin in patients hospitalized for acute heart failure, including the primary win-ratio endpoint, secondary analyses, statistical methodology, safety, and interpretation.
- ENDEAVORIndependent statistical analysis of the ENDEAVOR phase 3 trial of carfilzomib and dexamethasone versus bortezomib and dexamethasone in relapsed multiple myeloma, including progression-free survival, overall survival, response, safety, and statistical methodology.
- EPIC-HRIndependent statistical analysis of the EPIC-HR randomized phase 2/3 trial of PF-07321332/ritonavir versus placebo in nonhospitalized high-risk adults with COVID-19, including endpoint definitions, statistical methods, reported results, safety, and interpretation.
- EVOLVE-1Independent statistical analysis of the phase 3 EVOLVE-1 trial of galcanezumab for the prevention of episodic migraine, including randomized design, longitudinal mixed-effects analysis, odds ratios, Fisher exact testing, efficacy results, safety, and…
- EVOLVE-2Independent statistical analysis of the phase 3 EVOLVE-2 trial of galcanezumab for the prevention of episodic migraine, including trial design, registered endpoints, mixed-effects analyses, confidence intervals, secondary outcomes, safety information, and statistical…
- FINEARTS-HFIndependent statistical analysis of FINEARTS-HF, the randomized phase 3 trial evaluating finerenone versus placebo in participants with heart failure and left ventricular ejection fraction greater than or equal to 40%.
- FLAURAComplete statistical analysis of the phase 3 FLAURA trial of osimertinib versus standard-of-care EGFR-TKI therapy in locally advanced or metastatic EGFR sensitising mutation-positive non-small cell lung cancer.
- FLAURA2Independent statistical analysis of FLAURA2, the randomized phase 3 trial of osimertinib with chemotherapy versus osimertinib alone in first-line treatment of EGFR-mutated non-small cell lung cancer. Includes trial design, endpoints, survival analyses,…
- GRIPHONIndependent statistical analysis of the GRIPHON phase 3 trial of selexipag in pulmonary arterial hypertension, covering its randomized time-to-event endpoint, secondary analyses, statistical methods, confidence intervals, and interpretation.
- IMpassion131Independent statistical analysis of IMpassion131, a randomized phase 3 trial of atezolizumab plus paclitaxel versus placebo plus paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer.
- IMpower133Independent statistical analysis of IMpower133 (NCT02763579), a randomized phase 3 trial of atezolizumab plus carboplatin and etoposide versus placebo plus carboplatin and etoposide in untreated extensive-stage small cell lung cancer.
- INBUILDIndependent statistical analysis of the INBUILD phase 3 trial of nintedanib in patients with progressive fibrosing interstitial lung disease, including FVC decline, longitudinal modeling, time-to-event endpoints, logistic regression, safety, and interpretation.
- ISABELA 1Independent statistical analysis of ISABELA 1 (NCT03711162), a randomized phase 3 study of GLPG1690 in idiopathic pulmonary fibrosis, including FVC decline, disease progression, hospitalization, mixed-effects models, logistic regression, Cox models, and safety.
- ISABELA 2Complete statistical analysis of the ISABELA 2 phase 3 trial of GLPG1690 in idiopathic pulmonary fibrosis, including trial design, FVC decline, disease progression, hospitalization, survival endpoints, safety, statistical methodology, and interpretation.
- JAVELIN Head and Neck 100Independent statistical analysis of JAVELIN Head and Neck 100, a randomized phase 3 trial comparing avelumab plus standard of care chemoradiotherapy with placebo plus standard of care chemoradiotherapy in squamous cell carcinoma…
- KRYSTAL-12Independent statistical analysis of KRYSTAL-12, the phase 3 randomized trial of adagrasib versus docetaxel in patients with advanced non-small cell lung cancer with a KRAS G12C mutation.
- LUME-Lung 1Complete statistical analysis of LUME-Lung 1, the phase 3 randomized trial of BIBF 1120 plus docetaxel versus placebo plus docetaxel in second-line non-small cell lung cancer, including time-to-event, response, disease-control, quality-of-life, and…
- LUME-Lung 2Independent statistical analysis of LUME-Lung 2, a randomized phase 3 trial of nintedanib plus pemetrexed versus placebo plus pemetrexed in second-line nonsquamous non-small-cell lung cancer, including progression-free survival, overall survival, response, disease…
- LUX-Lung 6Independent statistical analysis of LUX-Lung 6, the randomized phase 3 trial comparing afatinib with gemcitabine-cisplatin chemotherapy in first-line non-small cell lung cancer. Includes progression-free survival, response, overall survival, quality-of-life endpoints, statistical methods,…
- LUX-Lung 7Independent statistical analysis of LUX-Lung 7, the randomized phase 2 trial comparing afatinib with gefitinib in first-line EGFR mutation-positive lung adenocarcinoma, including survival, response, quality-of-life, and safety analyses.